Last reviewed · How we verify
Short regimen of benznidazole
Short regimen of benznidazole is a Nitroimidazole antiparasitic Small molecule drug developed by Laboratorio Elea Phoenix S.A.. It is currently in Phase 3 development for Chagas disease (Trypanosoma cruzi infection) — acute and chronic phases. Also known as: Benznidazole 2 weeks.
Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and cellular structures of Trypanosoma cruzi parasites.
Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and cellular structures of Trypanosoma cruzi parasites. Used for Chagas disease (Trypanosoma cruzi infection) — acute and chronic phases.
At a glance
| Generic name | Short regimen of benznidazole |
|---|---|
| Also known as | Benznidazole 2 weeks |
| Sponsor | Laboratorio Elea Phoenix S.A. |
| Drug class | Nitroimidazole antiparasitic |
| Target | Trypanosoma cruzi DNA and cellular proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Benznidazole is activated by parasite enzymes to form reactive intermediates that bind to and damage parasite DNA and proteins, leading to cell death. It is used to treat Chagas disease, a parasitic infection caused by Trypanosoma cruzi. The short regimen formulation aims to improve treatment compliance and reduce cumulative toxicity while maintaining efficacy.
Approved indications
- Chagas disease (Trypanosoma cruzi infection) — acute and chronic phases
Common side effects
- Peripheral neuropathy
- Rash / dermatitis
- Gastrointestinal disturbances
- Headache
- Bone marrow suppression
Key clinical trials
- Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients (PHASE3)
- Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease (PHASE3)
- Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Short regimen of benznidazole CI brief — competitive landscape report
- Short regimen of benznidazole updates RSS · CI watch RSS
- Laboratorio Elea Phoenix S.A. portfolio CI
Frequently asked questions about Short regimen of benznidazole
What is Short regimen of benznidazole?
How does Short regimen of benznidazole work?
What is Short regimen of benznidazole used for?
Who makes Short regimen of benznidazole?
Is Short regimen of benznidazole also known as anything else?
What drug class is Short regimen of benznidazole in?
What development phase is Short regimen of benznidazole in?
What are the side effects of Short regimen of benznidazole?
What does Short regimen of benznidazole target?
Related
- Drug class: All Nitroimidazole antiparasitic drugs
- Target: All drugs targeting Trypanosoma cruzi DNA and cellular proteins
- Manufacturer: Laboratorio Elea Phoenix S.A. — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Parasitology
- Indication: Drugs for Chagas disease (Trypanosoma cruzi infection) — acute and chronic phases
- Also known as: Benznidazole 2 weeks
- Compare: Short regimen of benznidazole vs similar drugs
- Pricing: Short regimen of benznidazole cost, discount & access